IVI in the Media

Maeil Business Newspaper | All music is beautiful in its own way, but Violinist Sang Hee Lee’s music shines a special light

Nature | Six months of COVID vaccines: what 1.7 billion doses have taught scientists

Asian Boss | We Asked Top Vaccine Expert About COVID Vaccine Problems

Bloomberg | Consequences of ‘Huge’ Global Gap in Vaccinations

EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?

Asia Times | Vaccinations in a race against viral variants

Nature | Why COVID vaccines are so difficult to compare

DEVEX | Opinion: COVAX — too big, and too important, to fail

CNN | “Our response needs to be clear, strong, and unified”

South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think

Bloomberg | Will the Covid-19 Vaccines Be Effective and Safe?

Asian Boss | Update On COVID-19 Vaccine Price & Schedule From A Leading Vaccine Expert

The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19

CGTN | ‘The vaccine itself is not the silver bullet,’ says International Vaccine Institute

Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine

Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea

Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines

Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions

The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line

Devex | Q&A: Is COVID-19 helping or hindering progress toward an HIV vaccine?

TED | The trials, tribulations and timeline of a COVID-19 vaccine

Wired Korea | The End of World War C: Peace without Victory?

Asian Boss | World’s Leading Vaccine Expert Fact-Checks COVID-19 Vaccine Conspiracy

Development Today | Why Sweden funds a vaccine institute in Korea and not Oslo-based CEPI

CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things

The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’

CGTN: The Agenda with Stephen Cole | Speed of vaccine trials is ‘unprecedented’

Asian Boss | We Asked The World’s Leading Vaccine Expert About COVID-19 Vaccine

The Guardian | Test, trace, contain: how South Korea flattened its coronavirus curve

BBC World Service: The Inquiry | How do we come out of the lockdown? (13:00)

ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine

Seeker | How Fast Can We Make a Coronavirus Vaccine?

Education City Speaker Series: Flattening the Curve – Global Responses to COVID-19

Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim

South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute

BBC World News | Jerome Kim: Vaccines are the long-term solution to the pandemic

The Korea Times | Developing vaccine against COVID-19

TRT: Bigger than Five | COVID-19: The World Reacts

South Korea’s fight against coronavirus (CBS News)

NDTV | Top South Korea Doctor On Why He Thinks Coronavirus Is Not A ‘Chinese Virus’

RTE | What South Korea can teach Ireland about fighting Covid-19

Physical distancing should last months, not weeks, says epidemiologist (Yahoo News Canada)

Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)

COVID-19 Pandemic (Arirang TV, 22:50~46:00)

By then, we’ll have a vaccine on our side (Hankyoreh—Korean)

Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)

Testing times: Why South Korea’s COVID-19 strategy is working (Al Jazeera English)

Genexine seeks to compress the vaccine timeline

Genexine, Binex to develop COVID-19 vaccine (Korea Biomedical Review)

Genexine, Binex to co-develop coronavirus vaccine GX-19 (Korea Herald)

How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)

COVID-19 vaccine, drugs on fast track for development: IVI chief (Yonhap News)

Inside the race to find a coronavirus vaccine (Devex)

Chinese students keen for turnaround (China Daily)

China Daily | S. Korea can try out makeshift hospitals, experts say

Director General Jerome Kim for Phoenix TV

Speed and accuracy vital for COVID-19 test kits (Arirang News)

2020 COVID-19 Live Updates: Jerome Kim for tbs eFM

Jerome Kim for KBS WORLD Radio, Korea24 on the COVID-19 outbreak in South Korea

Korea should join efforts in vaccine development to prevent pandemics (JoongAng Ilbo)

Future global health threats

IVI: COVID-19 could linger (Korean)

Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”

Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?

Al Jazeera English | Scientists call for global cooperation over coronavirus

When will COVID-19 vaccine be commercialized…And “super vaccine”? (Korean)

Global push to find vaccine against devastating bug growing

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

Korean vaccines expanding global territory

Neglected Victims of Neglected Diseases

Let’s build a common defense against epidemics

Vaccine investment brings 16-fold return… partnering with Bill Gates

World must join forces to prevent infectious diseases

IVI editorial in The Korea Herald advocates for Korean leadership for global health

×

13th Vaccinology Course Hosted by IVI Concludes Successfully

Author
Hong
Date
2013-05-20 00:00
Views
4540
 

13th International Advanced Course on Vaccinology, IVI’s Program to Increase Developing Country's Capacity in Vaccine Research and Immunization, Concludes Successfully

  • IVI's International Advanced Course on Vaccinology marks part of IVI's capacity-building effort to better equip healthcare professionals and decision-makers in developing nations.
  • A total of 67 participants from 22 countries took part in the 13th International Advanced Course on Vaccinology, which ran from May 13-18 at IVI headquarters.
  • Participants discussed historical perspectives of vaccines, new advances in vaccine R&D, and ethical principles in the design and conduct of vaccine studies and advocacy of vaccination, among other topics.

 

May 20, 2013, Seoul, South Korea— The International Vaccine Institute (IVI), the first international organization headquartered in South Korea, successfully concluded the 13th International Advanced Course on Vaccinology in the Asia-Pacific Region. The popular week-long course, the first vaccinology course of its kind in the Asia-Pacific region, aims to build capacity of health professionals and decision-makers, especially those from developing countries, in all areas of the vaccine spectrum: vaccine development, evaluation, production and policy.

 

This year, over 67 participants from 22 countries including, the Bangladesh, China, India, Nigeria, Sudan, Thailand and Vietnam participated in the course. The participants were a diverse mix of scientists, public health officials, and policymakers from private and public sectors including 14 fellowships.

 

“This year’s course focused on the vaccine development process, and the method for vaccine evaluation,” said Dr. Soon-Ae Kim, research scientist at IVI who worked as Course Coordinator. “The course also provided information on a range of vaccine-preventable diseases including Hepatitis E, Human Papilloma Virus, Tuberculosis, HIV, influenza and Malaria.”

 

 
Dr. Christian Loucq, Director General of the International Vaccine Institute, gives a speech at the 13th International Advanced Course on Vaccinology, which ran from May 13-18, 2013 in Seoul, Korea.

  

Lectures by leading experts in vaccinology, roundtable discussions, and interactive case studies were conducted on a wide range of disciplines, including epidemiology and immunology, the latest in vaccine technology, regulatory issues, and vaccine economics and financing. More than 30 experts from IVI, universities, research institutions, industry, non-profit organizations, and international agencies served as faculty members.

 

Dr. Gregory Dudley Hussey from the University of Cape Town, gave a keynote closing speech on May 18 entitled ‘Vaccine research and development: past, present and future.’ Dr. Francois Meurice, Vice president of Global Medical Affairs Scientific affairs and Medical Education at GlaxoSmithKline, also spoke on the method for vaccine evaluation through Phase I, II, and III clinical trial and post-licensure.

 

“IVI believes that capacity building is essential in ensuring that safe, effective, and affordable vaccines are discovered, developed and delivered to developing nations,” said Dr. Christian Loucq, IVI Director General. “We are thrilled to conclude yet another successful course on vaccinology, and we look forward to continuing to provide high quality training for healthcare professionals to ensure vaccines are utilized in mitigating infectious disease risk.”  

 

The course was supported by GlaxoSmithKline Biologicals, Pfizer Corporation Hong Kong Limited the Korea Exchange Bank Foundation, the Export Import Bank of Korea, as well as the Korean Ministry of Education.

 

About IVI

The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 30 countries of Asia, Africa and Latin America on vaccines against diarrheal infections, bacterial meningitis and pneumonia, as well as Japanese encephalitis and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit www.ivi.int.

 

 

Media Contact:

IVI

Tae Kyung Byun

Public Awareness/Advocacy Officer, IVI

Phone: +82-2-872-2801 (Ext. 159)

Mobile: +82-11-9773-6071

Email: tkbyun@ivi.int

 

Burson-Marsteller Korea

Lirah Lim

Phone: +82-3782-6469

Mobile: +82-10-2081-0643

Email: lirah.lim@bm.com

 

Nicolle Kuritsky

Phone: +82-3782-6460

Mobile: +82-10-3889-8902

Email: nicolle.kuritsky@bm.com

 

 

DONATE